Ledipasvir

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Ledipasvir is a Hepatitis C Virus NS5A Inhibitor. The mechanism of action of ledipasvir is as a P-Glycoprotein Inhibitor, and Breast Cancer Resistance Protein Inhibitor.

Ledipasvir, also known as GS-5885; is an inhibitor of the hepatitis C virus NS5A protein and is a drug for the treatment of hepatitis C that was developed by Gilead Sciences. On October 10, 2014 the FDA approved the combination product ledipasvir 90 mg/sofosbuvir 400 mg (trade name Harvoni). The ledipasvir/sofosbuvir combination is a direct-acting antiviral agent that interferes with HCV replication and can be used to treat patients with genotypes 1a or 1b without PEG-interferon or ribavirin.

GS5885; GS-5885; GS 5885; Ledipasvir

Cell Cycle/DNA Damage

HDAC

GT1a; GT1b

Infection

——

1256388-51-8

889

C49H54F2N8O6

98%

DMSO : 50 mg/mL. 56.24 mM;H2O : < 0.1 mg/mL

O=C(OC)N[C@H](C(=O)N1[C@H](c2ncc(c3cc4C(F)(F)c5c(ccc(c6ccc7nc([C@H]8N(C(=O)[C@@H](NC(=O)OC)C(C)C)[C@@H]9CC[C@H]8C9)[nH]c7c6)c5)c4cc3)[nH]2)CC2(C1)CC2)C(C)C

Methyl N-[(2S)-1-[(6S)-6-[5-[9,9-Difluoro-7-[2-[(1S,2S,4R)-3-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-3-azabicyclo[2.2.1]heptan-2-yl]-3H-benzimidazol-5-yl]fluoren-2-yl]-1H-imidazol-2-yl]-5-azaspiro[2.4]heptan-5-yl]-3-methyl-1-oxobutan-2-yl]carbamate

(-20℃)

With Ice Pack

≥ 2 years